Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Statement | 16 December 2025 Governments must take concrete actions to ensure equitable access to medical tools for noncommunicable diseases and mental health conditions
Issue brief | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Issue brief | 26 March 2026 EthiopiaNigeriaSouth Sudan Antimicrobial Resistance in Conflict-Affected Settings: Field Realities, Operational Challenges & Policy Insights
Press release | 24 March 2026 MSF demands sustained investments and political will to end neglect of children with tuberculosis
Interview | 24 March 2026 How TB Treatment Decision Algorithms Help Diagnose Children: A Paediatrician’s Experience
Letter | 16 March 2026 European Union Open letter: The Critical Medicines Act must deliver equitable, affordable access to medicines for all
Press release | 05 March 2026 DNP+ and MSF welcome the removal of harmful IP provisions in EU-India FTA , but call for continued vigilance
Technical brief | 09 February 2026 Ensuring Collective Efforts Deliver Equitable Access Through the WHO PABS System
UN Photo/Christopher Black Events Events | 01 February 2022 MSF 150th EB Statement about non-State actors in WHO’s governing system 2 min
Technical brief | 28 January 2022 COVID-19 South Africa Removing intellectual-property barriers from COVID-19 vaccines and treatments for people in South Africa
UN Photo/Christopher Black Events Events | 24 January 2022 MSF statement at WHO Executive Board 150th Session 2 min
Photograph by Nikhil Roshan Press release Press release | 14 January 2022 COVID-19 MSF responds to latest WHO recommendation for a COVID-19 therapeutic, baricitinib 3 min
Newsletter Newsletter | 01 January 2022 Diabetes HIV/AIDS Tropical & neglected diseases Vaccines Our Wishlist for 2022
Photograph by Pierre Fromentin Press release Press release | 23 December 2021 COVID-19 MSF responds to FDA approval of COVID-19 drug molnupiravir 3 min
Photograph by Chris Allan Press release Press release | 22 December 2021 COVID-19 MSF responds to FDA approval of COVID-19 treatment nirmatrelvir/ritonavir 5 min